Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Rivero

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|September 17, 2021
Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745Joseph E Pero, John J McAtee, David J Behm, et al.
Bioorganic & Medicinal Chemistry|December 10, 2002
2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in ratsKevin Pan, Malcolm K Scott, Daniel H S Lee, et al.
Journal of Medicinal Chemistry|November 17, 2020
Design and Optimization of an Acyclic Amine Series of TRPV4 Antagonists by Electronic Modulation of Hydrogen Bond InteractionsJaclyn R Patterson, Lamont R Terrell, Carla A Donatelli, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR AgonistsBrian Budzik, Vincenzo Garzya, Dongchuan Shi, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2008
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamidesJian Jin, Ming An, Anthony Sapienza, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β InhibitorsHongyi Yu, Michael L Moore, Karl Erhard, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 14, 2022
Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse modelChristina Gross, Anwesha Banerjee, Durgesh Tiwari, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 1, 2018
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse modelChristina Gross, Anwesha Banerjee, Durgesh Tiwari, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2012
Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitorsRobert M Sanchez, Karl Erhard, Mary Ann Hardwicke, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2008
Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureasJian Jin, Yonghui Wang, Dongchuan Shi, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|September 17, 2021
Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745Joseph E Pero, John J McAtee, David J Behm, et al.
Bioorganic & Medicinal Chemistry|December 10, 2002
2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in ratsKevin Pan, Malcolm K Scott, Daniel H S Lee, et al.
Journal of Medicinal Chemistry|November 17, 2020
Design and Optimization of an Acyclic Amine Series of TRPV4 Antagonists by Electronic Modulation of Hydrogen Bond InteractionsJaclyn R Patterson, Lamont R Terrell, Carla A Donatelli, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR AgonistsBrian Budzik, Vincenzo Garzya, Dongchuan Shi, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2008
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamidesJian Jin, Ming An, Anthony Sapienza, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β InhibitorsHongyi Yu, Michael L Moore, Karl Erhard, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 14, 2022
Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse modelChristina Gross, Anwesha Banerjee, Durgesh Tiwari, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 1, 2018
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse modelChristina Gross, Anwesha Banerjee, Durgesh Tiwari, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2012
Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitorsRobert M Sanchez, Karl Erhard, Mary Ann Hardwicke, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2008
Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureasJian Jin, Yonghui Wang, Dongchuan Shi, et al.
Pageof 4